Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced positive top-line Phase II study results for its novel ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 ...

Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ETCompany ParticipantsBryan Giraudo - COO & CFOFaheem Hasnain ...

Clinical programs on track, with two major milestones later this year, and cash position, CHF 131 million as of March 31, 2025, expected to provide funding well into 2027IND filing and initial clinica ...

Our cells have limited energy that can quickly be depleted, and so they will prioritise what job to do.” You may like Here’s ...

Toothaches can be sharp, throbbing, or constant—and finding fast relief is important. Over-the-counter pain relievers like ibuprofen, naproxen, or acetaminophen are often the first line of defense, ...

C3's recent deployment on Roche IVD platforms, the new Endotrophin assay strengthens risk stratification and pharmacodynamic monitoring. Endotrophin was first identified in 2012 as a collagen-derived ...

But I'll dive, more deeply, into that, in a moment. Now, this year, we've experienced great momentum in rolling the study, as growing appreciation of the 72-week TORREY open-label extension data from ...

Telix Pharmaceuticals excels in radiopharmaceuticals, with strong revenue growth driven by imaging products like Illuccix.

It is still far too early to officially label Crews as a bust. But with every passing day, and every game he plays in without finding that groove, the time comes closer and closer.